Biora Therapeutics, Inc. BIORQ
0.00
(0.22)
(100.00%)
as of 24 Sep
- Market cap
- $2.5M
- P/E
- 0.0×
Follow BIORQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
121.86% | 108.06% | 82.39% | 27.98% | |
| (292.93%) | (290.85%) | (254.92%) | (128.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
290.36% | 308.84% | 243.75% | 27.81% | |
Average Days of Receivables |
0.00 | 535.77 | 347.26 | 354.38 | |
Free Cash Flow per Share |
(30.81) | (16.72) | (13.57) | (1.26) | |
Free Cash Flow |
(48.59) | (48.98) | (48.47) | (46.18) | |
Capital Expenditures |
(0.09) | (0.08) | (0.24) | (0.26) | |
Piotroski F-Score |
— | 3.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
119.76% | 110.85% | 125.85% | 54.86% | |
Accounts Receivable Turnover |
0.00 | 0.68 | 1.05 | 1.06 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 5,295.18% | 3,631.25% | 2,957.16% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 6,786.79% | 4,334.84% | 3,951.68% | |
Share Based Compensation of Revenue |
0.00% | 2,791.07% | 1,757.99% | 664.32% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.39 | 0.44 | 0.56 | 1.46 | |
Depreciation/Fixed assets |
1.87 | 3.24 | 2.82 | 3.52 | |
Capex/Depreciation |
(0.04) | (0.02) | (0.07) | (0.06) | |
Revenue per Share |
0.00 | 0.19 | 0.24 | 0.02 | |
Operating CF per Share |
(30.75) | (16.69) | (13.50) | (1.26) | |
Capex per Share |
(0.06) | (0.03) | (0.07) | (0.01) | |
Capex to Sales |
0.00 | 0.14 | 0.28 | 0.29 | |
Net Profit Margin |
0.00% | (19,796.96%) | (10,022.11%) | (3,527.85%) |
Columns are period end dates